Multi-antigen-directed Autologous T-cells NEXI-002

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-cells targeting several multiple myeloma (MM)-associated antigens, with potential immunomodulating and antineoplastic activities. Peripheral blood mononuclear cells (PBMC) from the patient are collected and ex vivo exposed to nanoparticles that mimic antigen-presenting cells (APCs) loaded with multiple MM-associated antigens, including Wilms' tumor 1 (WT1), CD138 (syndecan-1; SDC1), cancer-testis antigen NY-ESO-1 and CS1 (CD319; CRACC; SLAMF7), and are further enriched and expanded ex-vivo before being re-introduced into the patient. Upon administration, the multi-antigen-directed autologous T-cells NEXI-002 are re-introduced into the patient, where they target and kill tumor cells expressing these antigens.

**Synonyms:** - Autologous MM-associated Antigens Specific T Cells NEXI-002 - NEXI 002 - NEXI-002 - NEXI-002 T Cells - NEXI002 - TAA Primed Antigen-specific CD8+ T Cells NEXI-002